Company intelligence / Profile preview
Apmonia Therapeutics
Strasbourg, Grand Est, Franceapmonia-therapeutics.com ↗
- Ownership
- Private
- Employees
- ~50
- Development stage
- Preclinical
01
Overview
Apmonia Therapeutics has developed a first-in-class therapeutic peptide (TAX2) targeting TSP-1 in the tumor microenvironment. The company aims to combine this therapy with a companion diagnostic kit for patient stratification. Recent funding and collaborations are supporting advancement toward clinical trials, but no published late-stage clinical results yet.
- Therapeutic areas
- Oncology
- Modalities
- Peptides (notably therapeutic peptides)immunotherapy
- Industry
- Biotech
02
Drug pipeline
2 assets1 more asset in the full pipeline.
03
Partnerships
SATT Nord (licensing and co-development agreement)Max Mousseron Institute of Biomolecules / IBMM (collaboration in molecular modeling)Bpifrance as public sector investor/funder
Beyond the preview
Go deeper on Apmonia Therapeutics.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Apmonia Therapeutics.